Skip to main content
. 2021 Nov 17;81(18):2091–2101. doi: 10.1007/s40265-021-01631-w

Fig. 2.

Fig. 2

Consistency in response to DaxibotulinumtoxinA for Injection (DAXI) treatment across Phase 2 and 3 clinical trials. Response was defined as achievement of none or mild glabellar line (GL) severity at maximum frown based on investigator assessment via the validated 4-point Investigator Global Assessment-Frown Wrinkle Severity score (ranging from none [0] to severe [3]). OLS open-label study